Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis

Conclusion Adult patients with RA discontinuing TNFi therapy who switched to an alternative TNFi incurred lower healthcare costs than patients who switched to a non-TNFi biologic. Funding AbbVie, Inc.

http://link.springer.com/10.1007/s12325-016-0318-5

Source: Advances in Therapy - March 23, 2016 Category: Drugs & Pharmacology Source Type: research